Biotalys NV (EBR:BTLS)

Belgium flag Belgium · Delayed Price · Currency is EUR
3.105
+0.010 (0.32%)
Jul 1, 2026, 5:35 PM CET
Market Cap116.65M -28.8%
Revenue (ttm)n/a
Net Income-15.76M
EPS-0.42
Shares Out 37.57M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,186
Open3.195
Previous Close3.095
Day's Range3.080 - 3.195
52-Week Range1.560 - 5.280
Beta1.40
AnalystsBuy
Price Target5.03 (+62.0%)
Earnings DateAug 20, 2026

About Biotalys NV

Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN... [Read more]

Sector Materials
Founded 2013
Employees 62
Stock Exchange Euronext Brussels
Ticker Symbol BTLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for BTLS stock is "Buy." The 12-month stock price target is €5.03, which is an increase of 62.00% from the latest price.

Price Target
€5.03
(62.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biotalys Secures EPA Approval For EVOCA, First Protein-Based Biofungicide

(RTTNews) - Biotalys (BTLS.BR) announced that the U.S. Environmental Protection Agency (EPA) has granted regulatory approval for its breakthrough biofungicide, EVOCA. Developed using the company's pro...

7 months ago - Nasdaq